GHGuangyuan Hu

Guangyuan Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guangyuan Hu has a total of 228 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoyu Li

    Department of Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    18 shared publications
  • Na Luo

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    14 shared publications
  • Feng Yang

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    13 shared publications
  • Min Fu

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    13 shared publications
  • Wenjun Zhu

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    13 shared publications
  • Yiling Zhang

    Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    11 shared publications

Latest Publications

  • Open Access

    Lipid Droplet Remodeling at the Glia–Neuron Interface: Metabolic Sinks, Flux Traps, and Therapeutic Pitfalls in Neurodegeneration

    by Min Fu, Yizhen Su, Guangyuan Hu, Xiaoxiao Luo

    Neurodegenerative diseases are characterized by progressive neurological decline, metabolic dysfunction, and chronic neuroinflammatory changes. Dysregulated lipid handling has emerged as an important component of these processes, but the functional significance of lipid droplets (LDs) remains strongly context-dependent. Here, we review LD biogenesis, turnover, and cell type-specific functions in the central nervous system (CNS) and critically evaluate evidence linking LD remodeling to neurodegeneration. Transient LD formation can buffer excess or oxidation-prone lipids and support metabolic adaptation, whereas persistent lipid retention in the setting of impaired lysosomal, mitochondrial, or lipid-export capacity is associated with cellular dysfunction. We compare human tissue data, genetic evidence, LD-specific perturbations, pharmacological studies, and experimental models across Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD). Particular attention is given to microglial lipid-associated states, neuron–glia lipid transfer, monogenic disorders of lipid handling, and apparently opposing outcomes of LD manipulation in different disease contexts. Rather than treating LD accumulation as a universal pathogenic mechanism, we propose LD remodeling as a candidate metabolic–inflammatory convergence state whose functional consequences depend on cell type, lipid composition, turnover capacity, and disease stage. Translational strategies should therefore prioritize direct measurements of LD flux, demonstration of CNS target engagement, and biomarker-guided patient and disease-stage selection. We further define experimental findings that would support or falsify the proposed convergence model.

  • Open Access

    Research Progress and Challenges in Targeting GLUT1 in Tumors

    by Taohua Chen, Bi Peng, Xinya Yuan, Yizhou Liu, Jianing Zhang, Yizhen Su, Guangyuan Hu, Zhen Tao, Guoxian Long

    The solute carrier family 2 member 1 (SLC2A1), which encodes glucose transporter 1 (GLUT1), has long been recognized as a key driver of aerobic glycolysis in cancer. However, accumulating evidence has substantially expanded this view, revealing that GLUT1 functions not only as a critical mediator of metabolic reprogramming but also as an important regulator linking tumor metabolism to immune evasion. Notably, GLUT1 expression, regulation, and functional dependence are highly context-dependent across tumor types, disease states, and cellular compartments. Recent studies further link GLUT1-dependent glycolytic flux to immune regulation through glucose competition, lactate accumulation, and metabolite-dependent epigenetic programs within the tumor microenvironment. Reflecting this evolving understanding, therapeutic strategies targeting GLUT1 have progressed from simple metabolic inhibition to approaches that exploit tumor-specific metabolic dependencies and extend to regulated cell death, combination therapy, precision delivery, and selective modulation of malignant and non-malignant cellular compartments. These advances support a shift from expression-centered targeting toward strategies guided by functional GLUT1 dependence and cellular context, while recognizing the metabolic and physiological constraints that shape the therapeutic window. In this review, we systematically summarize recent advances in GLUT1 expression heterogeneity, multilayered regulatory networks, metabolic–immune crosstalk, diagnostic and prognostic relevance, and therapeutic targeting, and discuss how these insights may refine biomarker development, patient selection, and the clinical translation of GLUT1-directed precision metabolic therapy.

  • Open Access

    Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    by Jinguan Lin, Song Qu, Kunyu Yang, Tao Zhang, Yuansong Bai, Jian Wu, Yanjing Huang, Meiyu Fang, Xianling Liu, Xiaoming Huang, et al.

    Background: Effective treatment options remain limited for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), including patients who have progressed after platinum‐based chemotherapy and systemic‐therapy‐naïve patients. This Phase Ib trial evaluates the efficacy and safety of finotonlimab, a PD‐1 antibody, combined with SCT200, an EGFR antibody. Methods: This prospective, multicenter, open‐label study enrolled patients into two cohorts: Cohort A (previously treated with platinum‐based chemotherapy and immune checkpoint inhibitors) and Cohort B (systemic therapy‐naïve). Patients received finotonlimab (200 mg every 3 weeks) and SCT200 (6 mg/kg weekly for 12 weeks, then 8 mg/kg every 2 weeks). The primary endpoint was objective response rate (ORR). Results: Among 41 patients, Cohort A ( n = 11) showed an ORR of 27.3%, median progression‐free survival (PFS) of 5.8 months, and median overall survival (OS) of 10.6 months. Cohort B ( n = 30) had an ORR of 56.7%, median PFS of 9.6 months, and an estimated median OS of 13.6 months. Common treatment‐related adverse events included hypomagnesemia (63.4%), rash (41.5%), and acneiform dermatitis (36.6%), which were manageable. Conclusions: The combination of finotonlimab and SCT200 demonstrates promising efficacy, particularly in systemic therapy‐naïve patients, warranting further investigation. Trial Registration: ClinicalTrials.gov identifier: NCT05552807; Chinadrugtrials.org.cn identifier: CTR20220917

  • Open Access

    Effects of proton therapy on the tumor immune system and clinical implications: A review

    by Rundong Liu, Mei Tao, Min Fu, Yingjia Hu, Zhen Tao, Guangyuan Hu

    Proton therapy, an emerging radiation therapy technique, has gained significant attention owing to its unique physical properties and biological effects. This review aims to explore the impact of proton therapy on the tumor immune system and of its combination with other therapies. This review outlines the fundamental principles and oncological applications of proton therapy, followed by an analysis of its impact on the immune system—encompassing draining lymph nodes, peripheral blood immune cells, tumor cell immune responses, and the tumor microenvironment. We further discuss current combinatorial strategies with immunotherapy and/or chemotherapy, which point toward promising clinical directions.

  • Open Access

    CALB2 Expression Is Associated with Tumor Progression and Prognosis in Colorectal Adenocarcinoma

    by Feng Yang, Yizhou Liu, Na Luo, Qianxia Li, Guangyuan Hu

    Background: Globally, colorectal adenocarcinoma (COAD) continues to be one of the most frequent contributors to cancer-associated deaths, pointing out an ongoing demand for robust biomarkers capable of reflecting disease advancement and predicting patient outcomes. Calbindin 2 (CALB2), a calcium-binding protein, has been implicated in tumor progression in several malignancies, but the precise functional involvement of this molecule in COAD remains insufficiently characterized. This study aimed to examine the clinical relevance and functional significance of CALB2 in COAD. Methods: Clinical tissue-based analyses, bioinformatic analyses of publicly available datasets, in vitro and in vivo functional assays, and targeted metabolomic profiling were performed to evaluate CALB2 in COAD. Results: Immunofluorescence analysis of a COAD tissue microarray revealed that CALB2 expression was more frequently detected in stage III tumors and was associated with the proliferation marker Ki67. The Cancer Genome Atlas (TCGA) cohort’s bioinformatic analyses revealed an increase in CALB2 expression with advancing pathological T stage, and it was associated with poorer overall survival. Functional experiments demonstrated that CALB2 expression accelerated tumor growth in vivo and promoted the migration and proliferation of colorectal adenocarcinoma cells in vitro. At the molecular level, altered CALB2 expression was associated with changes in epithelial–mesenchymal transition-related markers, p53 Ser33 phosphorylation, and amino acid-related metabolic profiles. Conclusions: Collectively, these findings show a correlation between CALB2 expression and poor clinical outcomes and disease progression in colorectal adenocarcinoma.

  • A Phase II Trial of Neoadjuvant Albumin-Bound Paclitaxel plus Carboplatin Combined with Tislelizumab in Locally Advanced HNSCC: Efficacy and Biomarker Exploration

    by Qianxia Li, Min Fu, Dong Kuang, Chu Pan, Yi Huang, Lanjun Cai, Jing Zhao, Ping Huang, Chao He, Kai Xu, et al.

    Purpose: The aim of this study was to evaluate the efficacy of neoadjuvant chemotherapy (albumin-bound paclitaxel + carboplatin) combined with the PD-1 inhibitor tislelizumab in patients with potentially resectable stage II to IVb head and neck squamous cell carcinoma (HNSCC) and explore immune and circulating tumor–related features potentially associated with treatment response. Patients and Methods: This was a single-arm phase II trial involving 33 patients with potentially resectable stage II to IVb HNSCC. Participants received two cycles of neoadjuvant therapy followed by surgery. Primary endpoints were pathologic complete response (pCR) rate and major pathologic response (MPR) rate. Safety and exploratory analyses, including circulating tumor cells (CTC), PD-L1 expression, and T-cell senescence, were also assessed. Results: The study demonstrated an objective response rate of 72.7% (24/33) and an R0 resection rate of 93.1% (27/29) in surgical patients. The pCR rate was 44.8%, and the MPR rate was 62.1%. The laryngeal preservation rate was 70.4% (19/27). With a median follow-up of 20.5 months, the 12- and 24-month event-free survival rates were 93.1% (95% confidence interval, 84.3%–100%). Five of six patients with decreased CTC levels achieved MPR (5/6, 83.3%). Among patients whose T-cell senescence decreased, four of six achieved MPR, whereas only two of five with increased T-cell senescence achieved MPR. The pCR rate was significantly higher in patients with PD-L1 combined positive score ≥ 1 compared with those with combined positive score < 1 (55.6% vs. 12.5%). Conclusions: Neoadjuvant immunochemotherapy improves pathologic response and organ preservation in stage II to IVb HNSCC. Dynamic changes in CTCs and T-cell senescence are associated with treatment efficacy, suggesting their potential as early, noninvasive indicators of response, supporting precision treatment strategies for locally advanced HNSCC.


  • Open Access

    Association of systemic immune-inflammation index (SII) with epigenetic age acceleration in adults: insights from NHANES

    by Rundong Liu, Mingjie Liu, Chendong Wang, Zhen Tao, Guangyuan Hu

    The Systemic Immune-Inflammation Index (SII), a marker of systemic inflammation, has been linked to various age-related diseases, but its association with Epigenetic Age Acceleration (EAA) remains underexplored. This study aimed to investigate the SII and EAA relationship. We analysed data from 1,915 participants from the National Health and Nutrition Examination Survey (NHANES). SII was calculated as platelet count × (neutrophil count/lymphocyte count). EAA was defined as HorvathAccel, HannumAccel, Skin&BloodAccel, PhenoAgeAccel, GrimAge2Accel, and DunedinPoAm. These metrics were derived utilizing the residual method. Multivariate linear regression, smooth curve fitting, threshold effect analyses, and subgroup analyses were employed to assess the relationship between the SII and EAA. Higher SII levels were significantly associated with HannumAccel, PhenoAgeAccel, GrimAge2Accel, and DunedinPoAm. Threshold effect analyses revealed non-linear relationships, with inflection points at SII values of 24.200, 12.553, 7.766, and 10.133, respectively. Subgroup analyses identified sex, age, poverty-to-income ratio, and marital status as significant effect modifiers. The elevated SII was associated with accelerated epigenetic ageing.


  • Open Access

    Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment

    by Rundong Liu, Chendong Wang, Zhen Tao, Guangyuan Hu

    This review delves into the characteristics of lipid metabolism reprogramming in cancer cells and immune cells within the tumor microenvironment (TME), discussing its role in tumorigenesis and development and analyzing the value of lipid metabolism-related molecules in tumor diagnosis and prognosis. Cancer cells support their rapid growth through aerobic glycolysis and lipid metabolism reprogramming. Lipid metabolism plays distinct roles in cancer and immune cells, including energy supply, cell proliferation, angiogenesis, immune suppression, and tumor metastasis. This review focused on shared lipid metabolic enzymes and transporters, lipid metabolism-related oncogenes and non-coding RNAs (ncRNAs) involved in cancer cells, and the influence of lipid metabolism on T cells, dendritic cells (DCs), B cells, tumor associated macrophages (TAMs), tumor associated neutrophils (TANs), and natural killer cells (NKs) within TME. Additionally, the role of lipid metabolism in tumor diagnosis and prognosis was explored, and lipid metabolism-based anti-tumor treatment strategies were summarized, aiming to provide new perspectives for achieving precision medicine.


  • Open Access

    Depression and Anxiety After Radiation-Induced Brain Injury: A Review of Current Research Progress

    by Feng Yang, Rundong Liu, Xiaohong Peng, Na Luo, Min Fu, Wenjun Zhu, Qianxia Li, Guangyuan Hu

    Radiation therapy serves as a fundamental treatment for primary and metastatic brain tumors, whether used alone or combined with surgery and chemotherapy. Despite its oncological efficacy, this treatment paradigm frequently induces radiation-induced brain injury (RBI), a progressive neuropathological condition characterized by structural and functional damage to healthy cerebral parenchyma. Patients with RBI frequently develop affective disorders, particularly major depressive disorder and generalized anxiety disorder, which profoundly impair psychosocial functioning and quality of life. The pathophysiology involves complex mechanisms such as neuroinflammation, oxidative stress, blood–brain barrier disruption, and white matter damage. Current management strategies include antidepressants, corticosteroids, and neuroprotective agents, while emerging therapies targeting neuroinflammation and neural repair show promise. This review comprehensively examines the pathogenesis of RBI-related affective disorders and evaluates both conventional and novel treatment approaches. By synthesizing current evidence, we aim to provide insights for developing more effective interventions to improve patient outcomes and quality of life.


  • Top Cited Papers
    Open Access

    Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges

    by Qiang Zhang, Wan Zhang, Xinya Yuan, Xiaohong Peng, Guangyuan Hu

    With the global trend of population aging becoming increasingly pronounced, the incidence of central nervous system (CNS) disorders continues to rise, posing a significant challenge to public health systems worldwide. Currently, many CNS disorders lack effective treatments, prompting researchers to investigate the therapeutic potential of natural compounds. Urolithin A (UA), a gut microbiota-derived metabolite of ellagitannins and ellagic acid, can cross the blood–brain barrier and exhibits a favorable safety profile. This review summarizes the biosynthesis, pharmacokinetic profile, and key biological effects of UA, including its promotion of mitophagy and mitochondrial homeostasis, as well as its anti-inflammatory, antioxidant, anti-senescence, and anti-apoptotic properties. We comprehensively summarize the preclinical evidence demonstrating UA’s therapeutic potential in CNS disorders, such as Alzheimer’s disease, Parkinson’s disease, and stroke. Recent clinical trials involving UA are presented, followed by a thorough analysis of the challenges associated with translating UA-based interventions into clinical practice for CNS disorders. This work aims to support the development of UA-based therapies to improve patient outcomes and address the growing global burden of CNS disorders.